Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
It is high time that India assumed a leadership role in healthcare.
99% of Pristyn Doctors are using EMR facility on its doctor app
The funding round also saw participation from some of India's top angel investors and leading industry giants
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Subscribe To Our Newsletter & Stay Updated
